Profile data is unavailable for this security.
About the company
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
- Revenue in USD (TTM)987.67m
- Net income in USD-294.33m
- Incorporated1987
- Employees1.54k
- LocationNovavax Inc700 Quince Orchard RoadGAITHERSBURG 20878United StatesUSA
- Phone+1 (240) 268-2000
- Fax+1 (302) 636-5454
- Websitehttps://www.novavax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MannKind Corp | 248.37m | 11.74m | 1.84bn | 414.00 | 186.79 | -- | 106.40 | 7.42 | 0.0359 | 0.0359 | 0.834 | -0.8226 | 0.656 | 2.85 | 9.71 | 599,937.20 | 3.10 | -26.07 | 4.05 | -37.80 | 71.29 | 59.68 | 4.73 | -57.61 | 3.76 | 1.86 | 1.89 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Kiniksa Pharmaceuticals Ltd | 338.93m | -10.23m | 1.87bn | 297.00 | -- | 4.29 | -- | 5.52 | -0.1788 | -0.1788 | 4.68 | 6.12 | 0.6602 | 1.41 | 15.03 | 1,141,179.00 | -1.99 | -16.49 | -2.29 | -18.72 | 87.73 | -- | -3.02 | -53.64 | 3.16 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Mirum Pharmaceuticals Inc | 264.38m | -109.16m | 1.88bn | 294.00 | -- | 8.17 | -- | 7.10 | -2.40 | -2.40 | 5.81 | 4.81 | 0.4788 | 5.06 | 5.52 | 1,001,424.00 | -19.77 | -38.93 | -23.38 | -44.88 | 72.27 | -- | -41.29 | -190.71 | 3.09 | -- | 0.573 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -253.26m | 1.94bn | 268.00 | -- | 5.05 | -- | -- | -2.79 | -2.79 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -55.77 | -35.26 | -60.57 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0522 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Akero Therapeutics Inc | 0.00 | -204.18m | 1.94bn | 61.00 | -- | 2.43 | -- | -- | -3.41 | -3.41 | 0.00 | 11.53 | 0.00 | -- | -- | 0.00 | -26.71 | -37.73 | -27.66 | -40.13 | -- | -- | -- | -- | -- | -- | 0.042 | -- | -- | -- | -35.46 | -- | -- | -- |
| Recursion Pharmaceuticals Inc | 49.64m | -374.93m | 1.96bn | 500.00 | -- | 3.34 | -- | 39.46 | -1.63 | -1.63 | 0.2155 | 2.08 | 0.0688 | -- | 17.80 | 99,270.00 | -51.98 | -- | -60.35 | -- | 17.15 | -- | -755.37 | -- | -- | -- | 0.0504 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Novavax Inc | 987.67m | -294.33m | 2.00bn | 1.54k | -- | -- | -- | 2.03 | -2.76 | -2.76 | 7.41 | -2.70 | 0.5638 | 21.98 | 4.63 | 640,095.30 | -16.80 | -46.06 | -78.53 | -269.57 | 63.67 | -- | -29.80 | -75.94 | 1.03 | -18.79 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Neumora Therapeutics Inc | 0.00 | -274.18m | 2.04bn | 108.00 | -- | 5.34 | -- | -- | -1.66 | -1.66 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -71.73 | -- | -76.67 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Soleno Therapeutics Inc | 0.00 | -65.41m | 2.05bn | 33.00 | -- | 7.21 | -- | -- | -2.43 | -2.43 | 0.00 | 7.31 | 0.00 | -- | -- | 0.00 | -39.04 | -53.90 | -41.25 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Fortrea Holdings Inc | 2.88bn | -228.20m | 2.14bn | 16.00k | -- | 1.46 | -- | 0.7433 | -2.56 | -3.23 | 32.30 | 16.33 | 0.7262 | -- | 3.48 | 159,794.40 | -5.76 | -- | -7.11 | -- | 17.17 | -- | -7.93 | -- | -- | -0.3374 | 0.4348 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Beam Therapeutics Inc | 352.57m | -143.01m | 2.15bn | 436.00 | -- | 2.51 | -- | 6.09 | -1.76 | -1.76 | 4.35 | 10.37 | 0.2696 | -- | -- | 808,639.90 | -10.94 | -24.54 | -12.84 | -29.26 | -- | -- | -40.56 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Keros Therapeutics Inc | 271.00k | -168.05m | 2.15bn | 149.00 | -- | 4.93 | -- | 7,936.41 | -5.13 | -5.13 | 0.0082 | 11.64 | 0.0007 | -- | -- | 1,992.65 | -41.43 | -35.95 | -43.43 | -38.07 | -- | -- | -62,012.55 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -100.44m | 2.22bn | 136.00 | -- | 2.41 | -- | -- | -2.24 | -2.24 | 0.00 | 16.10 | 0.00 | -- | -- | 0.00 | -17.07 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Maravai Lifesciences Holdings Inc | 278.59m | -132.08m | 2.23bn | 580.00 | -- | 5.10 | -- | 8.00 | -0.998 | -0.998 | 2.09 | 1.73 | 0.1501 | 3.07 | 6.36 | 428,592.30 | -8.74 | 12.67 | -11.38 | 15.46 | 46.73 | 74.79 | -58.24 | 37.32 | 9.28 | -1.59 | 0.4167 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
Data as of Sep 19 2024. Currency figures normalised to Novavax Inc's reporting currency: US Dollar USD
36.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 13.73m | 8.58% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 10.42m | 6.51% |
| Shah Capital Management, Inc.as of 30 Jun 2024 | 9.66m | 6.04% |
| D. E. Shaw & Co. LPas of 30 Jun 2024 | 6.32m | 3.95% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 6.07m | 3.79% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.20m | 2.00% |
| Coatue Management LLCas of 30 Jun 2024 | 2.62m | 1.64% |
| Voloridge Investment Management LLCas of 30 Jun 2024 | 2.11m | 1.32% |
| BMO Asset Management Corp.as of 30 Jun 2024 | 2.02m | 1.26% |
| Jane Street Capital LLCas of 30 Jun 2024 | 1.88m | 1.18% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
